Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-REGN3767
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-DFO-REGN3767 is a radiolabeled monoclonal antibody-based imaging agent used for positron emission tomography (PET) imaging. It consists of REGN3767 (fianlimab), a human monoclonal antibody targeting lymphocyte activation gene-3 protein (LAG3), conjugated to the chelator desferrioxamine (DFO) and labeled with the radioisotope zirconium-89 (^89Zr). The drug enables non-invasive PET imaging to detect LAG3-expressing tumors, providing information on biodistribution and target engagement in patients with cancer, particularly those with relapsed or refractory diffuse large B-cell lymphoma and advanced solid tumors. Its mechanism of action is based on specific binding to LAG3 expressed on tumor-infiltrating immune cells, allowing visualization of immune checkpoint expression in vivo[2][3][4][9].
- Other names
- zirconium Zr 89-DFO-fianlimabFianlimab DFO Zr-89
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)
Beyond the preview
Go deeper on 89Zr-DFO-REGN3767.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-REGN3767.